December 2016 Newsletter

December 15, 2016:

Continuing Weakness in Refractive Market Dampens US Ophthalmic Procedure Growth

MIGS technology remains key driver of glaucoma surgery volume.

December 15, 2016:

Slowdown in FLACS Market May be Steeper than Forecast

Alcon’s reported decline in LenSx sales reflects issues weighing on segment.

December 15, 2016:

Allergan/AqueSys XEN Receives FDA Clearance

The MIGS implant is indicated for refractory glaucoma cases.

December 15, 2016:

Ophthotech’s Fovista Fails to Meet Primary Endpoint in Phase III trials

The company has raised $740 million through venture capital, public offerings, and licensing deals.

December 15, 2016:

Frinzi to Lead Abbott Medical Optics after J&J Acquisition

He took the helm in January and said he was involved in finding “the right home” for the unit.

December 15, 2016:

Sun Pharma Gains US FDA Approval for BromSite for Cataract Patients

The product will be launched by US-based Sun Ophthalmics, likely before the end of 2016, the company said.

December 15, 2016:

Private Equity Firm Ardian Acquires Majority Stake in Schwind

The Schwind family will retain a significant interest, and Rolf Schwind will remain CEO.

December 15, 2016:

Ellex Raises $10.3 Million to Support Sales of iTrack Microcatheter

Australia-based company plans to increase sales force.

December 15, 2016:

Market Report: New Drugs and Procedures Will Drive Dry Eye Market, Along with Better Access

The segment is expected to grow to nearly $4.5 billion by 2021.

December 15, 2016:

Studies Show Need for Valid LASIK Questionnaire, Authors Say; Data Subset Creates Firestorm

One notable finding was participants reported more visual symptoms on the questionnaire than to their health care professionals.

December 15, 2016:

What’s in 21st Century Cures Act for Ophthalmic Industry?

The legislation is designed to speed drug and device approval by the US FDA.

December 15, 2016:

Allergan Vows to Fight Mylan Challenge to Restasis Patents

The drugmaker expects a decision in the fourth quarter of 2017.

December 15, 2016:

Amgen, Allergan Seek Marketing Approval in Europe, US for Avastin Biosimilar

US retina specialists use Avastin off-label in more than 50 percent of cases of wet AMD, according to Market Scope surveys.

December 15, 2016:

December 2016 News Briefs

Social media